Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Mar;63(3):454–456. doi: 10.1038/bjc.1991.105

Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.

V Hug 1, S Kau 1, G N Hortobagyi 1, L Jones 1
PMCID: PMC1971863  PMID: 1825919

Full text

PDF
454

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blossey H. C., Wander H. E., Koebberling J., Nagel G. A. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer. 1984 Sep 15;54(6 Suppl):1208–1215. doi: 10.1002/1097-0142(19840915)54:1+<1208::aid-cncr2820541319>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  2. Donckier J. E., Michel L. A., Buysschaert M. Cushing syndrome and medroxyprogesterone acetate. Lancet. 1990 May 5;335(8697):1094–1094. doi: 10.1016/0140-6736(90)92663-3. [DOI] [PubMed] [Google Scholar]
  3. Hortobagyi G. N., Hug V., Buzdar A. U., Kau S. W., Holmes F. A., Fritsche H. A. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer. 1989 Sep 1;64(5):1002–1006. doi: 10.1002/1097-0142(19890901)64:5<1002::aid-cncr2820640505>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  4. Pannuti F., Longhi A., Martoni A., Piana E., Baroni M. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients. Chemioterapia. 1987 Dec;6(6):396–398. [PubMed] [Google Scholar]
  5. Siminoski K., Goss P., Drucker D. J. The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med. 1989 Nov 1;111(9):758–760. doi: 10.7326/0003-4819-111-9-758. [DOI] [PubMed] [Google Scholar]
  6. Vignon F., Derocq D., Chambon M., Rochefort H. Les protéines oestrogéno-induites sécrétées par les cellules mammaires cancéreuses humaines MCF7 stimulent leur prolifération. C R Seances Acad Sci III. 1983 Jan 24;296(3):151–156. [PubMed] [Google Scholar]
  7. Willemse P. H., Dikkeschei L. D., Tjabbes T., van Veelen H., Sleijfer D. T. Adrenal steroids as parameters of the bioavailability of MA and MPA. Eur J Cancer. 1990 Mar;26(3):359–362. doi: 10.1016/0277-5379(90)90234-k. [DOI] [PubMed] [Google Scholar]
  8. van Veelen H., Willemse P. H., Sleijfer D. T., Sluiter W. J., Doorenbos H. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. Cancer Treat Rep. 1985 Sep;69(9):977–983. [PubMed] [Google Scholar]
  9. van Veelen H., Willemse P. H., Sleijfer D. T., van der Ploeg E., Sluiter W. J., Doorenbos H. Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother Pharmacol. 1985;15(2):167–170. doi: 10.1007/BF00257530. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES